In general, the intraventricular administration of cytotoxic antitumor drugs provides a high drug concentration in the cerebrospinal ‰uid with a reduced risk of systemic adverse reactions. Methotrexate (MTX) high-dose therapy requires close monitoring when performed in combination with trimethoprim-sulfamethoxazole (ST) therapy and proton pump inhibitor (PPI) and nonsteroidal anti-in‰ammatory drug administration for excretion delay and toxicity enhancement. While the frequency of systemic side eŠects is thought to be low with intrathecal administration, such eŠects do rarely but occasionally occur. We must consider drug interactions with combination therapy as a potential factor inducing such eŠects. We examined the patients who received MTX intrathecal administration at Fukuoka University Hospital from January 2013 to December 2014 with respect to the onset of side eŠects and combination therapy. MTX intrathecal administration was performed a total of 79 times in 27 patients. Inˆve of these 27 patients, MTX intrathecal administration was performed twice a week, and hematotoxicity and non-hematotoxicity developed in two patients in whom ST was also administered. On the other hand, even if ST and/or PPI was administered, no side eŠects were observed in the patients administered levofolinate. 
◯ MTX/Ara-C/PSL ◯ MTX/HDC ◯  ◯  ◯  ◯  ◯  ◯  Concomitant drug Trimethoprim-Sulfamethoxazole ◯ ◯ ◯ -◯ - PPI - ◯ ◯ ◯ ◯ ◯ NSAIDs - ----- LV - -◯ -◯ ◯ Hematologic adverse event Leukopenia G4  ----- Anemia G2  ----- Thrombocytopenia G3  ----- Non hematologic adverse event Oral mucositis G2 G2 ---- Hepatic disorder -G2 ---- Renal dysfunction - -----
